Literature DB >> 28837722

Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections.

Jonathan Kimmelman1, Benjamin Carlisle1, Mithat Gönen2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28837722     DOI： 10.1001/jama.2017.11502

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours.

Authors:  Nathan D Gay; Derrick Tao; Vinay Prasad
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

Review 2.  Machine Learning and Radiogenomics: Lessons Learned and Future Directions.

Authors:  John Kang; Tiziana Rancati; Sangkyu Lee; Jung Hun Oh; Sarah L Kerns; Jacob G Scott; Russell Schwartz; Seyoung Kim; Barry S Rosenstein
Journal:  Front Oncol       Date:  2018-06-21       Impact factor: 6.244

3.  Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study.

Authors:  Benjamin Gregory Carlisle; Adélaïde Doussau; Jonathan Kimmelman
Journal:  BMJ Open       Date:  2020-02-17       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.